Grace Therapeutics, Inc. Depreciation Expense on Reclassified Assets
Grace Therapeutics, Inc. (GRCE) reported Depreciation Expense on Reclassified Assets of $94.00 thousand for the 3-month period ending 2022-06-30, per its 10-K filed 2023-06-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DepreciationExpenseOnReclassifiedAssets · last filed 2023-06-23
- Grace Therapeutics, Inc. depreciation expense on reclassified assets for the quarter ending 2022-06-30 was $94.00K.
| Period end | Depreciation Expense on Reclassified Assets 3 month | Depreciation Expense on Reclassified Assets 3 month as first filed |
|---|---|---|
| 2022-06-30 | $94.00K 10-K · filed 2023-06-23 | $167.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |